Asset Details
Do you wish to reserve the book?
Treatment with a Luteinizing Hormone–Releasing Hormone Agonist in Adolescents with Short Stature
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Treatment with a Luteinizing Hormone–Releasing Hormone Agonist in Adolescents with Short Stature
Do you wish to request the book?
Treatment with a Luteinizing Hormone–Releasing Hormone Agonist in Adolescents with Short Stature
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Treatment with a Luteinizing Hormone–Releasing Hormone Agonist in Adolescents with Short Stature
2003
Overview
Treatment with a luteinizing hormone–releasing hormone (LHRH) agonist increases adult height in children with precocious puberty. This study was designed to determine whether LHRH-agonist therapy would increase adult height in short adolescents with normally timed puberty. The adolescents had an increase of 0.6 in the standard-deviation score for height, as compared with the initially predicted adult height; however, bone mineral density was decreased.
An LHRH agonist cannot be recommended.
Puberty first accelerates the rate of growth and then induces epiphyseal fusion, terminating the growth of long bones.
1
In the 1970s, long-acting agonists of luteinizing hormone–releasing hormone (LHRH) were shown to suppress gonadotropin secretion. In children with LHRH-dependent precocious puberty, treatment with LHRH agonists slows bone maturation, delays epiphyseal fusion, and increases adult height.
2
–
7
Studies of patients with hypogonadotropic hypogonadism,
8
estrogen insensitivity,
9
or estrogen deficiency
10
have suggested that prolonging the period of growth by delaying senescence of the growth plate
11
can increase adult height. However, changes in the tempo of puberty within the normal range do not influence adult . . .
Publisher
Massachusetts Medical Society
Subject
/ Age
/ Biological and medical sciences
/ Child
/ Enzyme Inhibitors - adverse effects
/ Enzyme Inhibitors - pharmacology
/ Enzyme Inhibitors - therapeutic use
/ Female
/ Follicle Stimulating Hormone - blood
/ Growth Disorders - drug therapy
/ Height
/ Humans
/ Male
/ Pharmacology. Drug treatments
/ Triptorelin Pamoate - adverse effects
/ Triptorelin Pamoate - analogs & derivatives
